1296201-68-7

Basic information

• Product Name: IMidazo[1,2-a]pyridine-3-carboxylic acid, 7-chloro-, ethyl ester
• Synonyms: IMidazo[1,2-a]pyridine-3-carboxylic acid, 7-chloro-, ethyl ester;ethyl 7-chloroiMidazo[1,2-a]pyridine-3-carboxylate;7-Chloro-iMidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester
• CAS NO: 1296201-68-7
• Molecular Formula: C₁₀H₉ClN₂O₂
• Molecular Weight: 224.64366
• Mol File: 1296201-68-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: IMidazo[1,2-a]pyridine-3-carboxylic acid, 7-chloro-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: IMidazo[1,2-a]pyridine-3-carboxylic acid, 7-chloro-, ethyl ester(1296201-68-7)
• EPA Substance Registry System: IMidazo[1,2-a]pyridine-3-carboxylic acid, 7-chloro-, ethyl ester(1296201-68-7)

Safety Data

• Hazardous Substances Data: 1296201-68-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Imidazo[1,2-a]pyridine-3-carboxylic acid, 7-chloro-, ethyl ester is used as a key intermediate in the synthesis of drug candidates and the development of new active pharmaceutical ingredients. Its unique chemical structure and properties contribute to the creation of novel therapeutic agents with potential applications in various medical fields.
Used in Agrochemical Industry:
Imidazo[1,2-a]pyridine-3-carboxylic acid, 7-chloro-, ethyl ester has potential applications in the field of agrochemicals, particularly for the development of new pesticides and herbicides. Its chemical properties and reactivity make it a valuable component in the design and synthesis of innovative agrochemical products aimed at enhancing crop protection and yield.

Upstream product

• 19798-80-2 2-Amino-4-chloropyridine 
• 33142-21-1 ethyl 2-chloro-3-oxopropanoate 
• 1072-98-6 5-chloro-2-pyridylamine 
• 1027194-45-1 potassium (1E)-2-chioro-3-ethoxy-3-oxoprop-1-en-1-olate 

Downstream Products

• 1019022-33-3 7-chloro-imidazo[1,2-a]pyridine-3-carboxylic acid 

Relevant articles and documents

Synthesis and SAR studies of novel 1,2,4-oxadiazole-sulfonamide based compounds as potential anticancer agents for colorectal cancer therapy

A diverse series of 1,2,4-oxadiazoles based substituted compounds were designed, synthesized and evaluated as anticancer agents targeting carbonic anhydrase IX (CAIX). Initial structure-activity analysis suggested that the thiazole/thiophene-sulfonamide conjugates of 1,2,4-oxadiazoles exhibited potent anticancer activities with low μM potencies. Compound OX12 exhibited antiproliferative activity (IC50 = 11.1 μM) along with appreciable inhibition potential for tumor-associated CAIX (IC50 = 4.23 μM) isoform. Therefore, OX12 was structurally optimized and its SAR oriented derivatives (OX17-27) were synthesized and evaluated. This iteration resulted in compound OX27 with an almost two-fold increase in antiproliferative effect (IC50 = 6.0 μM) comparable to the clinical drug doxorubicin and significantly higher potency against CAIX (IC50 = 0.74 μM). Additionally, OX27 treatment decreases the expression of CAIX, induces apoptosis and ROS production, inhibited colony formation and migration of colon cancer cells. Our studies provide preclinical rational for the further optimization of identified OX27 as a suitable lead for the possible treatment of CRC.

IMIDAZO-CONDENSED BICYCLES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS (DDRS)

The invention provides a compound of formula (I) (Formula (I)) or a tautomeric form, stereochemically isomeric form, N-oxide, pharmaceutically acceptable salt or solvate thereof, wherein R2, R3, R4, Ra, Rb

SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS

Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal

BICYCLIC HETEROARYLS AS KINASE INHIBITORS

The invention is directed to heteroaryl compounds useful as inhibitors of various kinase enzymes. In various embodiments, the invention provides a heteroaryl compound having inhibitory bioactivity with respect to a Rho kinase, an AKT kinase, a p70S6K kinase, a LIM kinase, an IKK kinase, a Flt kinase, an Aurora kinase, or a Src kinase, or any combination thereof. Compounds of the invention include bicyclic heteroaryl compounds of formula (I), which can contain a bridging nitrogen atom at a ring junction. The invention further provides methods of synthesis of compounds of the invention, pharmaceutical compositions, pharmaceutical combinations, and methods of treatment of malconditions using compounds of the invention.

SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS

Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4 and R5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.